Table 2 Cases of post-vaccine acute cerebellar ataxia
| Â | Vaccination | Type of vaccine | Number of patients | Sex | Age of patients (years) | Latency time from vaccination | Causality according to the author | WHO causality assessment criteria | WHO causality assessment criteria reevaluation |
|---|---|---|---|---|---|---|---|---|---|
Cutroneo P. M. et al. 2014 [21] | Meningococcus C | Meningococcal group C conjugate vaccination | 1 | Female | 12 | 1Â day | Very likely | Yes | Very likely (authors followed the WHO criteria) |
Yonee K. et al. 2013 [41] | Human Papillomavirus | HPV-16/18 AS04-adjuvanted cervical cancer vaccine | 1 | Female | 12.5 | 12Â days | Very likely | Not declared | Very likely |
Deisenhammer F. et al. 1994 [18] | Hepatitis B | Booster bivalent HBV vaccination | 1 | Female | 26 | 10Â days | Probable | Previous publications | Probable |
Saito H. et al. 1989 [17] | Influenza, The vaccine contained | Hemagglutinin particles equivalent to influenza A/Kumamoto/37/79/(H1N1) Russian strain 250 CCA/ml, influenza A/Niigata/102/81(H3N2) 300 CCA/ml, and influenza B/Singapore /222/79 150 CCA/ml | 1 | Female | 5 | 8Â days | Probable | Previous publications | Probable |
Katafuchi Y. et al. 1989 [19] | DTP | N.A | 1 | Female | 1 y e 11Â months | 5Â h | Very likely | Previous publications | Not applicable (Japanese article, abstract in English) |
Sunaga Y. Et al. 1995 [20] | Varicella | N.A | 1 | Male | 2 | 10Â days | Possible | Previous publications | Possible |